Atrium Therapeutics, Inc. Common Stock (RNA) Stock Price

RNAStock

$7.67−84.28%52W

Market Cap$131.20M

P/E—

PEG Ratio—

Div yield—

Beta1.21

RNA Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-55.20%

Price vs S&P 500 (4W)-15.21%

VGM Score48.62

Book Value / Share (Quarterly)$12.54

P/TBV (Annual)0.80x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)58.44%

Cash Flow / Share (Quarterly)$-4.66

Price vs S&P 500 (YTD)-101.29%

Net Profit Margin (TTM)-209.23%

EPS (TTM)$-5.04

10-Day Avg Trading Volume0.25M

EPS Excl Extra (TTM)$-5.04

Revenue Growth (5Y)36.26%

EPS (Annual)$-2.89

ROI (Annual)-35.34%

Net Profit Margin (5Y Avg)-1796.59%

Cash / Share (Quarterly)$15.43

Revenue Growth QoQ (YoY)-71.11%

ROA (Last FY)-592.61%

Revenue Growth TTM (YoY)22.02%

EBITD / Share (TTM)$-5.18

ROE (5Y Avg)-28.11%

Operating Margin (TTM)-217.00%

Cash Flow / Share (Annual)$-2.49

P/B Ratio0.80x

P/B Ratio (Quarterly)1.07x

Net Income / Employee (Annual)$-1,053,200

EV / Revenue (TTM)2.39x

Net Interest Coverage (TTM)-2.35x

ROA (TTM)-58.64%

EPS Growth QoQ (YoY)13.99%

EPS Incl Extra (Annual)$-2.89

Current Ratio (Annual)0.07x

Quick Ratio (Quarterly)8.59x

3-Month Avg Trading Volume0.25M

52-Week Price Return-84.28%

Revenue / Employee (TTM)$877,800

Tangible BV / Share (Quarterly)$6.98

P/S Ratio (Annual)9.18x

Asset Turnover (Annual)2.23x

52-Week High$73.06

Operating Margin (5Y Avg)-1959.94%

EPS Excl Extra (Annual)$-2.89

CapEx CAGR (5Y)96.69%

26-Week Price Return-45.29%

Quick Ratio (Annual)0.03x

13-Week Price Return-36.87%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)8.73x

Enterprise Value$98.52M

Revenue / Share Growth (5Y)13.23%

Asset Turnover (TTM)0.28x

Revenue / Employee (Annual)$396,100

Pretax Margin (Annual)-266.64%

Cash / Share (Annual)$8.75

3-Month Return Std Dev60.64%

Net Income / Employee (TTM)$-1,836,600

ROE (Last FY)-36.27%

EPS Basic Excl Extra (Annual)$-2.89

Receivables Turnover (TTM)19.72x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-5.04

ROI (TTM)-44.34%

P/S Ratio (TTM)4.14x

Pretax Margin (5Y Avg)-1796.59%

Revenue / Share (Annual)$1.09

Tangible BV / Share (Annual)$8.29

Price vs S&P 500 (52W)-99.81%

EPS Growth TTM (YoY)8.34%

Year-to-Date Return-89.37%

5-Day Price Return-6.58%

EPS Normalized (Annual)$-2.89

ROA (5Y Avg)-24.50%

Net Profit Margin (Annual)-265.88%

Month-to-Date Return-7.37%

Cash Flow / Share (TTM)$-2.93

EBITD / Share (Annual)$-2.88

Operating Margin (Annual)-266.58%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-28.11%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-5.04

P/TBV (Quarterly)0.90x

P/B Ratio (Annual)0.76x

Pretax Margin (TTM)-209.57%

Book Value / Share (Annual)$8.29

Price vs S&P 500 (13W)-39.56%

Beta1.21x

P/FCF (Annual)3.05x

Revenue / Share (TTM)$2.41

ROE (TTM)-40.30%

52-Week Low$7.54

vGradeB

gGradeC

mGradeD

vgmGradeC

RNA Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 13, 2026	-$0.64	-$1.18	-84.37%(-$0.54)
Q1 2026	May 14, 2026	-$1.05	-$0.97	+7.62%(+$0.08)

RNA Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.00

4.14

4.13

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
RNAAtrium Therapeutics, Inc. Common Stock	B	C	D	4.1x	22.0%	—	—	$7.67
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About Atrium Therapeutics, Inc. Common Stock

Atrium Therapeutics develops RNA-based therapeutics for genetic forms of cardiomyopathy. The company's proprietary platform uses ligand-based targeting to deliver RNA therapies directly to heart tissue. Current pipeline programs focus on cardiomyopathies associated with PRKAG2 and PLN gene mutations.